TransMedics Group Director James R. Tobin Sells $380K of Stock
James R. Tobin, Director, sold 4,000 shares of TransMedics Group, Inc. at $94.98 a share, worth $380K in total on Nov 9, 2026. Shares held after the trade: 2,922 (-57.8%).
TransMedics Group reported total revenue of $203.0 million for the third quarter of 2026, a 41% increase year-over-year, driven by growth in both product and service revenue. Net income for the quarter was $17.1 million, down from $24.3 million in the prior year period, primarily due to increased operating expenses in research, development, and clinical trials.
TransMedics reported record third-quarter 2026 revenue of $203.0 million, a 41% increase year-over-year, driven by strong growth in both product and service revenue. The company achieved net income of $17.1 million and raised its full-year 2026 revenue guidance to a range of $764 million to $774 million.
“The third quarter of 2026 was the strongest in TransMedics’ history, with record revenue and record case volume. Importantly, we delivered these results despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO.”
Waleed Hassanein, MD, President and Chief Executive Officer
“We enter 2027 with strong momentum and a robust set of growth catalysts. ENHANCE Heart Part B and DENOVO Lung target large, untapped heart and lung segments, with two shots on goal in each through OCS and CHOPS.”
Waleed Hassanein, MD, President and Chief Executive Officer